Sudarshan sells VP4 Frankfurt for EUR 76.5 million and sharpens focus on pigments

Sudarshan Chemical Industries Limited used its September 1, 2026 investor presentation to explain a decisive portfolio move: the sale of its step-down wholly owned subsidiary, VP4 Frankfurt GmbH. The transaction is framed as a strategic exit from a non-core manufacturing asset that mainly serves another industry, while securing continuity of supply for Sudarshan’s own limited internal requirement.

The key numbers are simple and material. VP4 Frankfurt generated revenue of EUR 15.7 million in FY26 and EBITDA of EUR 4.1 million. In Q1FY27, it reported revenue of EUR 4.1 million and EBITDA of EUR 1.3 million. The deal values the asset at EUR 76.5 million, with expected closure in about 2 to 3 months. Management’s stated intent is to use proceeds primarily to prepay an acquisition loan, with the explicit goal of becoming a zero net debt or positive cash company.

At its core, this is a story about strategic clarity. Sudarshan is a pigments-focused business, but VP4 Frankfurt is a diketene and CKP plant. Its output flows mainly into food additives, not pigments. The company is selling an asset that is not central to its long-term direction, while keeping a long-term supply arrangement in place to protect operations that still depend on the intermediate.

What VP4 Frankfurt does and why it sat outside the core

VP4 Frankfurt GmbH operates a manufacturing facility for diketene and CKP, described in the presentation as crotanaldehyde-ketan-polymer. These chemicals serve different end uses, and the distribution of VP4’s production is the most direct explanation for the divestment.

The presentation breaks down the end-use mix of diketene and CKP as follows. Around 90 to 95 percent is sold to Nitrinova for food additives. Only about 5 percent is used by Sudarshan for arylides, linked to azo yellow pigment. A further 2 to 3 percent goes to other parties.

This mix matters. It means VP4 primarily exists to support another company’s functional food ingredients value chain, while Sudarshan relies on it for a narrow captive requirement. The strategic issue is not whether VP4 is profitable. The more important question is whether it belongs inside Sudarshan’s operating model and capital allocation priorities.

Management’s narrative is that it does not. VP4 is described as non-core, and the sale is positioned as a way to strengthen Sudarshan’s strategic focus and operational position by sharpening attention on the core pigments business. The company also addresses the obvious investor concern: supply continuity. Post closing, Nitrinova will supply the required quantity of diketene to Sudarshan, and the presentation states that a long-term supply contract is in place.

The buyer group and why the asset is strategic for them

The buyer is introduced as Celanese US Holdings LLC, but the structure includes three parties and a transition plan.

Nitrinova is described as a joint venture between Celanese Corporation and Mitsui and Co. It is also described as the discoverer and producer of the acesulfame-K sugar substitute, branded as Sunett, and as a producer and seller of preservatives such as sorbic acid and potassium sorbate.

The transaction logic for the buyer side is straightforward in the presentation. Diketene and CKP are important intermediates for functional food ingredients, including artificial sweetener acesulfame-K. That makes the VP4 plant a strong strategic fit with Nitrinova.

There is also a supply chain and geography angle. The presentation says that JV partner Mitsui required European-based diketene and CKP production, and that the VP4 plant is one of the very few left actually in operations. The deal is framed as providing Mitsui with upstream integration spanning raw material procurement through manufacturing and sale of finished products.

Celanese will acquire and operate the VP4 plant for a transitional period before ownership passes to Nitrinova. This transition structure is part of the execution story. It signals that the buyer group is planning for operational continuity and integration rather than a simple financial purchase.

Deal terms, financial profile, and balance sheet intent

Sudarshan has disclosed a limited but useful set of financial metrics for VP4, alongside the headline deal value and timeline.

VP4 plant performance is presented in EUR million. For FY26, revenue was EUR 15.7 million and EBITDA was EUR 4.1 million. For Q1FY27, revenue was EUR 4.1 million and EBITDA was EUR 1.3 million.

The deal value is EUR 76.5 million. Expected closure is stated as approximately 2 to 3 months. The sale is described as the sale of the VP4 Frankfurt GmbH investment by Sudarshan Germany Horizons GmbH.

The use of proceeds is clearly stated: these proceeds will be primarily utilized for prepayment of an acquisition loan. The expected outcome is also stated clearly: this will further strengthen the balance sheet, and the company will be a zero net debt or positive cash company.

Even without additional group-level disclosures in this presentation, the direction of travel is clear. Sudarshan is linking a portfolio exit to deleveraging. The investor implication is that management is treating this asset sale as a way to reduce financial risk and increase flexibility, rather than as a one-off gain.

Financial snapshot from the presentation

What changes for Sudarshan after closing

Operationally, Sudarshan’s direct exposure to diketene and CKP manufacturing reduces, but the company preserves access to the intermediate it needs for its pigments value chain.

The presentation is explicit that only a small proportion of VP4 production was used by Sudarshan for captive consumption. That detail helps explain why management believes the plant is better owned by a player for whom it is strategic, while Sudarshan can remain a customer for its limited needs.

The long-term supply contract with Nitrinova is central to this structure. It turns Sudarshan’s dependence into a commercial arrangement rather than an ownership arrangement. For investors, the core question becomes execution risk: whether the supply agreement provides the required reliability and economics over time. The company’s disclosure that the supply contract is long term is meant to address that concern, though the presentation does not provide contract duration or pricing details.

Financially, the stated objective is sharper. The proceeds are intended primarily to prepay an acquisition loan, which implies a conscious decision to trade off asset ownership for balance sheet strength. The company links this to an outcome that equity investors often value: reaching zero net debt or even moving to a positive cash position.

Strategically, the theme is focus. The management message is that pigments is the core, and the VP4 plant is a non-core asset that mainly serves food additives. In that framing, divesting VP4 is not a retreat. It is a decision to align capital and management attention with the business Sudarshan wants to lead.

Investor takeaways: strategic clarity backed by execution steps

Sudarshan’s VP4 Frankfurt divestment is best read as a focused portfolio correction with a balance sheet goal attached.

First, the asset being sold is not central to Sudarshan’s core identity. The plant produces diketene and CKP, and the presentation shows that 90 to 95 percent of production serves Nitrinova’s food additives business. Only around 5 percent supports Sudarshan’s use in arylides for azo yellow pigment.

Second, the buyer logic is credible. Nitrinova’s functional food ingredients portfolio relies on intermediates like diketene and CKP, and its joint venture structure with Celanese and Mitsui creates a natural strategic owner for the asset. The disclosure that the VP4 plant is one of the very few still operating in Europe adds context to why this specific site matters to Mitsui’s requirements.

Third, the transaction is tied to a concrete balance sheet action. With a disclosed deal value of EUR 76.5 million and a stated use of proceeds toward acquisition loan prepayment, the company is setting expectations of becoming zero net debt or positive cash.

Finally, Sudarshan has outlined a continuity plan for its own operations. With Nitrinova supplying the required quantity of diketene post closing under a long-term supply contract, the company is trying to keep the pigments value chain insulated from disruption.

The forward-looking message is not about expanding into a new segment. It is about disciplined execution: exit a non-core asset, protect supply for the limited internal need, and redeploy proceeds to strengthen the balance sheet. For investors, the quality of this decision will ultimately be judged on closing within the 2 to 3 month window, the actual impact on net debt, and the stability of supply terms once VP4 is no longer inside the group.